In the second half of 2025, GLP-1 microdosing went from a fringe idea to a mainstream product line. Noom, Found and Hims & Hers all launched programmes prescribing microdosed GLP-1s within a few months of each other, and smaller providers followed.
The pitch is intuitive and appealing: take a lower dose than the standard therapeutic protocol, pay less, experience fewer side effects, and still get benefit. Noom’s programme, for instance, is priced from $119 for the first month and $199 thereafter — below its standard GLP-1 plan.
The problem is what sits underneath the pitch. Reporting on the trend has been direct about it: there is no clinical evidence establishing that microdosed GLP-1s are effective for the outcomes they are marketed around. That is not a claim that microdosing cannot work — it is a statement about what has actually been demonstrated.
This article sets out what microdosing is, who offers it and at what price, what the evidence does and does not support, and how to think about it if a provider proposes it to you.
What You Need to Know Before Considering a Microdose Programme
There Is No Established Evidence Base
Reporting on the launch of microdose programmes across major telehealth platforms noted plainly that there is no clinical evidence establishing microdosed GLP-1s are effective for what they are marketed to do. Standard GLP-1 dosing protocols were established through large trials; microdosing was not.
Providers Sometimes Say So Themselves
EllieMD’s own materials state that its microdosing programmes are not intended for major weight loss, framing them around longevity and wellness instead. That is worth taking at face value: if substantial weight loss is your goal, a product that says it is not for that is not the product.
It Is Not the Same as Starting Low
Every standard GLP-1 protocol starts at a low dose and titrates up over weeks. That is titration, and it is well established. Microdosing means deliberately staying below the therapeutic range indefinitely — a different thing entirely.
The Price Advantage Is Real but Modest
Noom’s microdose programme is priced from $119 for the first month and $199 thereafter. Remedy Meds offers a microdose tier at $189. AgelessRx starts at $99. Several full-dose all-inclusive providers charge less than all of these.
Fewer Side Effects Is a Plausible Claim
GLP-1 side effects are broadly dose-related, so a lower dose producing fewer side effects is mechanistically reasonable. The open question is whether a dose low enough to avoid side effects is still high enough to produce meaningful benefit.
Longevity Claims Are Further From the Evidence Than Weight Claims
Microdose marketing increasingly emphasises inflammation, metabolic health and longevity rather than weight. Those endpoints are harder to measure, take longer to demonstrate, and have correspondingly less supporting evidence in this context.
What Microdosing Actually Means
A standard GLP-1 protocol has a defined structure. Semaglutide for weight management titrates from 0.25 mg upward over several months toward a maintenance dose of 2.4 mg; tirzepatide runs from 2.5 mg toward maintenance doses of 10 mg or higher. Those doses were established in the trials that produced the weight-loss results everyone cites.
Microdosing means deliberately using doses below that therapeutic range on an ongoing basis — not as a titration step on the way up, but as the destination.
This distinction gets blurred in marketing, and it matters. Everyone starts low. The question is whether staying low delivers anything, and that question has not been answered by the kind of evidence that established the standard protocols.
Titration Is Not Microdosing
Starting at 0.25 mg semaglutide and moving up over months is the standard protocol, designed to manage gastrointestinal side effects. It is well established and not controversial. Microdosing is the choice to remain below therapeutic doses indefinitely.
The Marketing Endpoints Have Shifted
Early microdose marketing emphasised weight loss with fewer side effects. Increasingly it emphasises metabolic balance, inflammation, energy and longevity. Those endpoints are harder to measure and further from the available evidence.
It Is Commercially Attractive to Providers
Reporting has noted that microdosing may help telehealth firms more than patients: a lower dose costs less to supply, opens a cheaper price tier, and widens the addressable market to people who would not qualify for or want full-dose therapy.
Who Offers Microdosing and What It Costs
Microdose programmes are now offered by both major platforms and smaller providers, at prices that undercut full-dose plans at the same company but frequently not the wider market.
| Provider | Programme | Published Pricing |
|---|---|---|
| Noom | Microdose GLP-1Rx | From $119 first month, $199 thereafter |
| Remedy Meds | Microdose tier | $189/month |
| AgelessRx | Microdosing GLP-1 | Starting at $99 |
| EllieMD | GLP-1 and GLP-1/GIP microdoses | Priced separately; company states not intended for major weight loss |
| Good Life Meds | Microdose GLP-1 | Priced separately; marketed around metabolic balance and energy |
| Found | Microdose programme | Launched alongside standard GLP-1 plans from $99 |
| Hims & Hers | Microdose programme | Launched 2025; confirm current pricing directly |
What the Evidence Supports, and What It Does Not
What is established: GLP-1 side effects are broadly dose-related. Gastrointestinal effects are most pronounced during titration and at higher doses, which is why every standard protocol escalates gradually. A lower dose producing fewer side effects is mechanistically plausible and consistent with what is known.
What is not established: that doses deliberately kept below the therapeutic range produce clinically meaningful weight loss, or that they deliver the metabolic, inflammatory and longevity benefits microdose marketing increasingly emphasises. Reporting on the sector’s move into microdosing stated directly that there is no clinical evidence establishing effectiveness for these claims.
There is also a straightforward practical point that gets lost. Real-world data has consistently shown that injectable GLP-1 receptor agonists produce less weight loss in practice than in clinical trials, driven substantially by early discontinuation and low maintenance dosing. In other words, patients who end up on lower doses than the protocol intends already lose less weight — which is the closest thing we have to evidence about what happens at sub-therapeutic dosing, and it does not support the marketing.
A Reasonable Case for Microdosing
A patient who genuinely cannot tolerate standard doses, and whose clinician judges that some GLP-1 exposure is better than none, is making a defensible individualised decision. That is different from microdosing being marketed as a product tier.
A Poor Reason to Microdose
Choosing a microdose plan because it is cheaper than the same provider’s full-dose plan, while expecting full-dose results. Several all-inclusive providers offer standard-dose therapy for less than most microdose tiers cost.
The Question to Ask Your Prescriber
What specific outcome is this dose expected to produce for me, and on what basis? A clinician proposing a microdose for a considered individual reason will have an answer. A platform offering it as a price tier may not.
Our Take
If your goal is meaningful weight loss, microdosing is not the route to it — and some providers say so themselves. EllieMD’s materials state its microdosing programmes are not intended for major weight loss. Take that at face value rather than hoping the marketing around it means otherwise.
Check the price comparison before you accept the premise. Microdose tiers are cheaper than full-dose plans at the same provider, which is what makes them feel like a bargain. But Noom’s microdose plan at $199 after the first month, and Remedy Meds’ at $189, both cost more than Coreage RX charges for standard-dose therapy at a flat $99 all-inclusive. The saving is relative to one provider’s own pricing, not to the market.
There is a legitimate individualised case, and it is worth distinguishing from the product. A patient who cannot tolerate standard doses, whose clinician judges that partial exposure is better than discontinuation, is making a reasonable decision with a doctor who knows them. That is not the same as a platform selling a lower dose as a cheaper tier to a patient it has never spoken to.
Ask one question if microdosing is proposed to you: what specific outcome is this dose expected to produce, and on what basis? The quality of the answer will tell you which of those two situations you are in.
Frequently Asked Questions
What is GLP-1 microdosing?
Microdosing means using GLP-1 doses deliberately kept below the standard therapeutic range on an ongoing basis, rather than titrating up to the maintenance doses used in the clinical trials that established these medications. It is distinct from titration, which every standard protocol includes.
Does GLP-1 microdosing work?
Reporting on the launch of microdose programmes across major telehealth platforms noted that there is no clinical evidence establishing that microdosed GLP-1s are effective for the outcomes they are marketed around. That does not prove they do nothing — it means the evidence that established standard dosing does not exist for microdosing.
Which companies offer GLP-1 microdosing?
Noom, Found and Hims & Hers all launched microdose programmes in 2025, and smaller providers including Remedy Meds, AgelessRx, EllieMD and Good Life Meds offer microdose tiers. Noom’s programme is priced from $119 for the first month and $199 thereafter; Remedy Meds offers a microdose tier at $189; AgelessRx starts at $99.
Is microdosing cheaper?
Cheaper than the same provider’s full-dose plan, usually yes. Cheaper than the market, often no. Noom at $199 after the first month and Remedy Meds at $189 both cost more than several all-inclusive providers charge for standard-dose therapy. Compare against the market, not against one provider’s own price list.
Will microdosing reduce side effects?
Plausibly. GLP-1 side effects are broadly dose-related, which is why standard protocols titrate gradually. The unresolved question is whether a dose low enough to substantially reduce side effects is still high enough to produce meaningful benefit.
Is microdosing the same as starting on a low dose?
No, and the distinction matters. Every standard GLP-1 protocol starts low and titrates up over weeks to manage side effects — that is titration, and it is well established. Microdosing means remaining below therapeutic doses indefinitely as the intended destination.
What about microdosing for longevity or inflammation?
These endpoints are further from the available evidence than the weight-loss claims, not closer. They are harder to measure, take longer to demonstrate, and there is no established clinical evidence base supporting microdosed GLP-1s for them. Treat longevity marketing with more scepticism than weight marketing, not less.
Should I consider microdosing?
If a clinician who knows your history proposes it for a specific reason — you could not tolerate standard doses, and partial exposure is judged better than stopping — that is a reasonable individualised decision. If you are selecting it from a menu because it is the cheaper tier, compare against standard-dose all-inclusive providers first; several cost less.
Disclosure:
This article is based on publicly available information including provider-published microdose programme descriptions and pricing, press and trade reporting on the launch of microdose GLP-1 programmes across major telehealth platforms, and published research on real-world GLP-1 effectiveness and maintenance dosing, current as of August 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews. Statements about the absence of an established evidence base reflect published reporting and the current state of clinical literature, and could change as research develops. Compounded medications are not FDA-approved. Nothing here is medical advice, and dosing decisions belong entirely to a clinician who knows your history. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This article is for informational purposes only and is not medical advice. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.
Related Guides & Articles
AgelessRx Review
The only microdose provider sponsoring a clinical trial to test whether it works.
Do GLP-1 Supplements Work?
The evidence behind products marketed as boosting your own GLP-1.
Oral GLP-1 Drops and Pills
Which non-injectable GLP-1 products have evidence behind them and which do not.
Best All-Inclusive GLP-1 Providers
Standard-dose therapy at prices below most microdose tiers.
Managing GLP-1 Side Effects
What to do about the side effects microdosing is marketed to avoid.
Compare All GLP-1 Providers
Read our independent reviews of every provider we cover
View All Reviews →